CY1694A - Ketone derivatives as medicaments for the treatment or prevention of the withdrawal syndrome - Google Patents

Ketone derivatives as medicaments for the treatment or prevention of the withdrawal syndrome

Info

Publication number
CY1694A
CY1694A CY169494A CY169494A CY1694A CY 1694 A CY1694 A CY 1694A CY 169494 A CY169494 A CY 169494A CY 169494 A CY169494 A CY 169494A CY 1694 A CY1694 A CY 1694A
Authority
CY
Cyprus
Prior art keywords
prevention
medicaments
treatment
withdrawal syndrome
ketone derivatives
Prior art date
Application number
CY169494A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CY1694A publication Critical patent/CY1694A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY169494A 1986-11-21 1994-01-14 Ketone derivatives as medicaments for the treatment or prevention of the withdrawal syndrome CY1694A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868627909A GB8627909D0 (en) 1986-11-21 1986-11-21 Medicaments

Publications (1)

Publication Number Publication Date
CY1694A true CY1694A (en) 1994-01-14

Family

ID=10607734

Family Applications (1)

Application Number Title Priority Date Filing Date
CY169494A CY1694A (en) 1986-11-21 1994-01-14 Ketone derivatives as medicaments for the treatment or prevention of the withdrawal syndrome

Country Status (16)

Country Link
US (1) US4847281A (xx)
EP (1) EP0278161B1 (xx)
JP (1) JPH0830008B2 (xx)
KR (1) KR950010148B1 (xx)
AT (1) ATE74271T1 (xx)
AU (1) AU608788B2 (xx)
CY (1) CY1694A (xx)
DE (1) DE3778008D1 (xx)
DK (1) DK612787A (xx)
ES (1) ES2033879T3 (xx)
GB (1) GB8627909D0 (xx)
GR (1) GR3004252T3 (xx)
HK (1) HK36793A (xx)
IE (1) IE61033B1 (xx)
PH (1) PH24934A (xx)
ZA (1) ZA878702B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198447A (en) * 1986-11-21 1993-03-30 Glaxo Group Limited Medicaments
JP2765845B2 (ja) * 1986-11-21 1998-06-18 グラクソ、グループ、リミテッド 中止症候群の予防の治療薬
US5198459A (en) * 1987-07-11 1993-03-30 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
US5272168A (en) * 1987-07-11 1993-12-21 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
GB8820650D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
US5292752A (en) * 1989-12-21 1994-03-08 Merrell Dow Pharmaceuticals Inc. Antithrombotic compounds
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5397782A (en) * 1990-06-13 1995-03-14 Janssen Pharmaceutica N.V. Method of treating addiction to alcohol
EP0591434A4 (en) * 1991-06-26 1994-09-14 Sepracor Inc Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
US5726644A (en) * 1995-06-30 1998-03-10 Philips Electronics North America Corporation Lighting control system with packet hopping communication
US5824684A (en) * 1997-02-21 1998-10-20 Synapse Pharmaceuticals International, Inc. Method for treating drug and alcohol addiction
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
WO2010065930A1 (en) * 2008-12-04 2010-06-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499096A (en) * 1983-11-18 1985-02-12 Lotsof Howard S Rapid method for interrupting the narcotic addiction syndrome
FI84349C (fi) * 1984-01-25 1991-11-25 Glaxo Group Ltd Foerfarande foer framstaellning av en farmakologiskt vaerdefull foerening.
DE3688296T2 (de) * 1985-03-14 1993-11-04 Beecham Group Plc Arzneimittel zur behandlung von erbrechen.
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
NL8701682A (nl) * 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
PH23937A (en) * 1986-12-16 1990-01-23 Robins Co Inc A H Anxiolytic-n-(1-azabicyclo(2.2.2.)oct-3-yl)benzamides and thiobenzamides
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten

Also Published As

Publication number Publication date
ATE74271T1 (de) 1992-04-15
GR3004252T3 (xx) 1993-03-31
JPH0830008B2 (ja) 1996-03-27
HK36793A (en) 1993-04-23
KR950010148B1 (ko) 1995-09-11
JPS63185927A (ja) 1988-08-01
EP0278161A1 (en) 1988-08-17
PH24934A (en) 1990-12-26
US4847281A (en) 1989-07-11
EP0278161B1 (en) 1992-04-01
DK612787A (da) 1988-05-22
DE3778008D1 (de) 1992-05-07
GB8627909D0 (en) 1986-12-31
AU8144387A (en) 1988-05-26
DK612787D0 (da) 1987-11-20
AU608788B2 (en) 1991-04-18
IE61033B1 (en) 1994-09-07
IE873156L (en) 1988-05-21
ES2033879T3 (es) 1995-04-01
KR880005930A (ko) 1988-07-21
ZA878702B (en) 1988-09-28

Similar Documents

Publication Publication Date Title
CY1694A (en) Ketone derivatives as medicaments for the treatment or prevention of the withdrawal syndrome
EP0392959A3 (en) Use of sertindole for the treatment of schizophrenia
AU2711295A (en) Combination treatment for inhibiting bone loss
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
AU8261787A (en) Medicaments for the treatment of depression
GR3006091T3 (xx)
HU901085D0 (en) Process for producing substituted benzimidazole and pharmaceutical preparatives containing it
CA2118512A1 (en) Agents for treating substance abuse disorders
AU1956092A (en) Pharmaceutical agent for treatment of withdrawal symptoms
SE8902458L (sv) Laekemedelskomposition
IE873231L (en) Medicaments
ZA872443B (en) Bis-tert.butylamino-substituted 1,3,5-triazine derivatives,processes for their preparation,medicaments containing these compounds and their use
IL98199A0 (en) Pharmaceutical compositions containing a derivative of substituted-l-valyl-l-prolinamide
IT1296613B1 (it) Farmaco per la cura dell'ircismo contenente un adrenocorticosteroide.
EP0457336A3 (en) Use of mizoribine for the treatment or prevention of multiple sclerosis
IL89654A (en) Pharmaceutical combination compositions for treating hypertension
MX9803271A (es) Uso de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,6-tetrahid ropiridina para la preparacion de farmacos para el tratamiento de esclerosis lateral aminotrofica.
MX9703032A (es) Nuevas aplicaciones del 5-etoxicarbonil-2,4,6-trimetil-1,4-dihidropiridina-3-carboxi lato de 2-[n-(1,2-benzisotiazolil-3(2h) ona-1,1-dioxido]etilo.